Cannabinoids in dermatologic surgery - 12/02/21

Doi : 10.1016/j.jaad.2021.01.016

Ha Eun Kong, PhD ^a, Brian P. Pollack, MD, PhD ^a,^b,^c,^d,^e, Travis W. Blalock, MD ^a,^b,^d,^e,^⁎
^a Emory University School of Medicine, Atlanta, Georgia
^b Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia
^c Department of Pathology, Emory University School of Medicine, Atlanta, Georgia
^d Winship Cancer Institute of Emory University School of Medicine, Atlanta, Georgia
^e Atlanta VA Health System, Decatur, Georgia

^∗Reprint requests: Travis W. Blalock, MD, Emory Clinic Department of Dermatology, 1525 Clifton Rd, Atlanta, GA 30322.Emory Clinic Department of Dermatology1525 Clifton RdAtlantaGA30322

Sous presse. Épreuves corrigées par l'auteur. Disponible en ligne depuis le Friday 12 February 2021
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder

Abstract

Though known as a medicinal herb for centuries, the recent legalization of cannabinoids across many states has ushered in a new era where cannabinoids have become a popular treatment option among clinicians and patients alike. Cannabinoids have demonstrated efficacy in wound healing, reducing inflammation, ameliorating pain, and have shown potential as an antitumor agent. As a result, cannabinoids have been rapidly woven into the fabric of modern medicine. However, the utility of cannabinoids in dermatologic surgery has not been explored to date. In this article, we review the current literature to discuss the potential impact of cannabinoid use in dermatologic surgery.

Le texte complet de cet article est disponible en PDF.

Key words : cannabidiol (CBD), cannabinoids, dermatologic surgery, inflammation, marijuana, pain, wound healing